Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors
Advancing targeted cancer immunotherapy is pivotal for overcoming distant metastasis and tumor relapse. The recent study in Nature Cancer by Sanlorenzo et al. demonstrates a breakthrough strategy combining systemic type I interferon with topical Toll-like receptor 7/8 agonists, where oral imiquimod...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2025-01-01
|
| Series: | Research |
| Online Access: | https://spj.science.org/doi/10.34133/research.0739 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Advancing targeted cancer immunotherapy is pivotal for overcoming distant metastasis and tumor relapse. The recent study in Nature Cancer by Sanlorenzo et al. demonstrates a breakthrough strategy combining systemic type I interferon with topical Toll-like receptor 7/8 agonists, where oral imiquimod primes plasmacytoid dendritic cells (DCs) to produce type I interferon, thereby sensitizing conventional DCs in tumors to local Toll-like receptor 7 activation. This approach triggers c-Jun-dependent IL-12 production and CCL2-mediated plasmacytoid DC recruitment, enabling localized and systemic tumor suppression. Importantly, the therapy synergizes with PD-1 blockade to prevent recurrence, representing a significant advance in DC-targeted cancer immunotherapy. |
|---|---|
| ISSN: | 2639-5274 |